Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation

Table 4 Univariate and multivariate analysis of the preoperative risk factors related to tumour recurrence

Risk factors	Univariate analysis			Multivariate analysis
	3-yr RFS rate (%)	HR (95%CI)	Log-rank P value	Exp(b) (95%CI)	P value
Pre-TACE radiological and laboratory evaluation
Exceeding Milan criteria	77.7 vs 91.2	3.41 (0.78-14.92)	0.074
Exceeding UCSF criteria	60.6 vs 92.8	5.06 (0.78-32.74)	0.011	4.69 (1.14-19.30)	0.033
Multiple nodules	77.2 vs 93.4	4.33 (1.06-17.72)	0.049	1.77 (0.27-11.48)	0.550
AFP > 400 ng/mL	80.0 vs 85.3	1.96 (0.13-30.81)	0.520
NLR > 4	100 vs 80.4	NA	0.185
PLR > 150	50.0 vs 88.6	5.98 (0.06-573.48)	0.059
Pre-LT radiological and laboratory evaluation
mRECIST non response	71.2 vs 94.3	6.96 (1.54-31.50)	0.006	9.19 (1.65-51.30)	0.012
EASL non response	76.8 vs 91.6	3.67 (0.82-16.34)	0.056
AFP > 400 ng/mL	83.3 vs 89.0	4.74 (0.29-77.77)	0.034	1.43 (0.23-9.10)	0.703
AFP increase > 15 ng/mL per month	41.7 vs 87.7	3.89 (0.30-50.72)	0.072
NLR > 4	80.8 vs 87.9	1.54 (0.25-9.41)	0.594
NLR increase > 0.24/mo	83.3 vs 100	NA	0.114
PLR > 150	50.0 vs 89.1	5.32 (0.28-101.01)	0.022	5.95 (1.04-33.95)	0.046
PLR increase > 3.04	80.8 vs 88.7	1.48 (0.24-9.04)	0.636

RFS: Recurrence-free survival; HR: Hazard ratio; TACE: Transarterial chemoembolization; USCF: University of California San Francisco; AFP: Alpha-fetoprotein; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LT: Liver transplantation; mRECIST: Modified Response Evaluation Criteria in Solid Tumours; EASL: European Association for the Study of the Liver.